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Figure 1. Comparison between the performance of 
radiochromic film and PUMA for analysis of motion effects on 
low modulated SABR lung plans 
Conclusions: PUMA can predict the interplay effect on SABR 
lung cancer patients and has the potential to be used as a 
routine method to ensure an appropriate low level of 
modulation on SABR lung plans independently of the energy. 
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Preclinical evaluation of novel anticancer agents combined to 
Ionizing Radiation (IR) is a key step in the generation of a 
sound rationale for further transfer towards the early clinical 
phases. Animal models should allow the minimal assessment 
of the toxicity hazard and provide significant signs of 
increased anti tumor efficacy, both required to address their 
clinical relevance, i.e. the therapeutic ratio of a candidate 
future combination. 
This assumption is clearly challenged by the major 
discrepancy between the amount of combinations suggested 
by preclinical data in the last decade and the fact that 
platinum based combinations remain the mostly widely used 
agents in the management of lung tumors. This not only 
illustrates the difficulties in funding the continuum from 
promising preclinical data to clinical steps, but also 
underscores the relatively low relevance of our preclinical 
models. Certainly, one of the reasons for this gap is the 
inhabitility of our preclinical models to keep up with the 
changes in the mutational landscape of lung cancer. Another 
major aspect is that most models used so far include 
immunocompromised models, which fail to recapitulate the 
importance of the tumor stroma in the processes of radiation 
response. The precise correlation between the preclinical 
judgment criteria and the medical need is also key : while 
most preclinical papers focus on tumor growth delays, the 
clinical need is to increase local control and to minimize the 
onset of metastasis. Lastly, the potential deleterious impact 
on normal tissues, both acute and long term, should also be 
properly evaluated at the preclinical stage to increase the 
accuracy of this appraisal. Preclinical models should also try 
to address the current challenges of the biomarker era and 
suggest in which biological context, and which criteria may 
be used to define the optimal biological context for patient 
selection. Importantly, integration of cisplatinum based 
chemotherapy as a reference may be useful for proper 
assessment of potential clinical gains. To conclude, 
immunological and vascular parameters can be dramatically 
affected by fractionation, fractionating irradiation is thus 
important for the evaluation of candidate combinations. 
Genetically engineered mice models and orthotopic murine 
models in immunocompetent recipient mice should markedly 
contribute to an improvement of the output of these murine 
models and eventually increase the success rates of future 
clinical trials while avoiding the transfer of uneffective or 
hazardous combinations to the patient. 
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Non-small cell lung cancer (NSCLC) is a group of different 
histologic tumor types with diverse molecular aberrations.  
Lung adenocarcinomas are now classified according to driving 
molecular abnormalities (mutations, rearrangements or 
amplifications), which can be identified in more than half of 
tumors, leading to effective systemic therapies in many of 
these patients. In contrast to that, evidence for presence of 
such abnormalities in squamous cell lung carcinomas is less 
clear. Successful combination of targeted therapies, 
chemotherapy and radiation in early NSCLC should be taken 
into account in the context of molecular drivers. In 
oncogenic-driven stage III NSCLC, it is likely that effective 
systemic treatment will be combined with radical 
radiotherapy or radiochemotherapy as a sequential 
 treatment, although evidence for such approach is currently 
lacking. RTOG 1306 phase II clinical trial is currently 
randomly allocating stage III patients with tumors showing 
EGFR mutations or ALK rearrangements to either 
radiochemotherapy alone (control group) or 12 weeks of 
erlotinib (EGFR cohort) or crizotinib (ALK cohort) followed by 
definitive radiochemotherapy. In non-oncogene addicted 
NSCLC, incorporation of targeted therapies into 
radiochemotherapy schedules is very difficult to predict 
preclinically, as demonstrated by several examples, including 
negative results of the RTOG 0617 trial. This trial failed to 
show any benefit from the addition of cetuximab, a 
monoclonal antibody targeting EGFR, into radiochemotherapy 
in stage III NSCLC. Lack of good prediction of clinical data 
may result from complex interactions among targeted agents, 
chemotherapy, and radiation. One of the most promising 
strategies for the future is related to the success of immune 
checkpoint inhibitors, which show considerable promise as 
adjuvant systemic treatment after definitive 
radiochemotherapy.  
Optimization of combined radiation and chemotherapy 
programs is still a matter of ongoing discussions and 
investigations. Although concurrent radiochemotherapy is a 
standard of care in fit stage III NSCLC patients, sequential 
treatments with cytotoxic agents followed by either 
hypofractionated or hyperfractionated accelerated 
radiotherapy schedules are currently revisited.  
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Purpose/Objective: IDEAL-CRT and I-START are phase I/II 
trials investigating isotoxic dose escalation in patients with 
stage IIa-IIIb non-small cell lung cancer. In both trials the 
